Takeda Pharmaceutical (NYSE:TAK) Releases Earnings Results, Beats Expectations By $0.37 EPS

Takeda Pharmaceutical (NYSE:TAK) announced its quarterly earnings data on Thursday. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37, Zacks reports. The company had revenue of $7.53 billion during the quarter, compared to analyst estimates of $7.34 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Takeda reported first-half core revenue of JPY 2.4 trillion, down 1% at constant exchange rates, while core operating profit rose 0.7% to JPY 710.6 billion. Full-year revenue guidance remains a low-single-digit decline, but core operating profit and EPS guidance were raised primarily due to favorable foreign exchange.
• Takeda has launched ORZEYFUL in Japan and China and expects a U.S. launch in early November, while MIMRYLO launched in the U.S. in August and is receiving positive physician and patient feedback. Zasocitinib filings were accepted for priority review in the U.S. and by European regulators, supporting potential approval and launch in fiscal 2026.
• The company’s transformation program is progressing, with approximately 3,000 impacted roles communicated and JPY 30 billion in annualized procurement savings implemented. Takeda remains on track for JPY 100 billion in gross savings, which management says is helping fund product launches and R&D investment.
• Late-stage pipeline data were encouraging: TAK-921 produced statistically significant progression-free and overall survival benefits in heavily pretreated gastric cancer, including an overall survival hazard ratio of 0.57, while ENTYVIO’s VERDICT study showed roughly a 70% reduction in ulcerative-colitis-related complications for patients treated to stringent targets.
• Zasocitinib’s ulcerative colitis study showed encouraging efficacy at the 50 mg dose, but not at 75 mg, creating uncertainty because there was no clear dose-response relationship; Takeda will wait for Crohn’s disease data expected around fiscal year-end before finalizing its phase III strategy. Plasma-derived therapies also faced near-term weakness in IVIG and albumin, with albumin forecasts reduced due to market conditions and Chinese cost-containment measures.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock traded up $0.92 during midday trading on Friday, reaching $20.93. The company had a trading volume of 4,540,833 shares, compared to its average volume of 3,021,581. The company has a market capitalization of $67.05 billion, a P/E ratio of 61.54 and a beta of -0.07. Takeda Pharmaceutical has a 12-month low of $13.35 and a 12-month high of $21.22. The firm’s fifty day simple moving average is $18.79 and its 200-day simple moving average is $17.52. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62.

Key Stories Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda reported quarterly adjusted earnings of approximately $0.48 per share, ahead of the $0.31 consensus estimate, while reported EPS was $0.51 versus expectations of $0.14. Revenue reached $7.53 billion, exceeding the $7.34 billion consensus. Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
• Positive Sentiment: The company raised its annual guidance after first-half profit growth, providing a near-term catalyst and signaling confidence in operating execution despite a generic-drug overhang. Takeda Pharmaceutical Raises Annual Guidance
• Positive Sentiment: Takeda secured approvals for ORZEYFUL (oveporexton) in the U.S., Japan and China, launched MIMRYLO (rusfertide) in the U.S., and advanced zasocitinib’s regulatory review. Management is targeting roughly $11 billion in peak sales from a trio of blockbuster candidates, supporting the longer-term growth story. Takeda Announces FY2026 First-Half Results Takeda Bets on Blockbuster Drug Trio
• Neutral Sentiment: Operating margin improved to 17%, partly because of lower amortization costs. However, Entyvio remains the primary revenue driver, while newer products have so far contributed only modestly as they ramp. Takeda Pharmaceutical’s Earnings Growth Has Yet to Translate to Higher Cash Flow
• Negative Sentiment: Operating cash flow declined to $2.74 billion, raising questions about the quality and durability of earnings. Analysts also cited the difficulty of replacing major drug revenues and viewed the current valuation as limiting upside, leading to a Hold stance. Cash Flow and Valuation Concerns

Insider Activity at Takeda Pharmaceutical

In other news, insider Deidre Greenway sold 12,980 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the transaction, the insider owned 40,049 shares in the company, valued at $725,287.39. This trade represents a 24.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Lauren Duprey sold 34,535 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the sale, the insider directly owned 191,522 shares in the company, valued at $3,550,817.88. This represents a 15.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 627,457 shares of company stock worth $10,981,175 in the last quarter. Corporate insiders own 0.04% of the company’s stock.

Analysts Set New Price Targets

TAK has been the topic of several research reports. Zacks Research downgraded shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 1st. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.